1. Indications and Usage
\nTreatment of Reflux Esophagitis (RE): Treatment of adult patients with reflux esophagitis .
\nHelicobacter pylori Eradication: Treatment of Helicobacter pylori-infected patients in combination with appropriate antibiotics (e.g., amoxicillin, clarithromycin) .
\n2. Dosage and Administration
\nAdministration: Oral administration. Can be taken with or without food .
\nReflux Esophagitis:
\nRecommended Dose: 20 mg once daily.
\nDuration: Most patients benefit within 4 weeks. If efficacy is insufficient, the course may be extended to a maximum of 8 weeks .
\nMaintenance: For maintenance therapy of recurrent RE, 10 mg once daily (may increase to 20 mg if ineffective) .
\nH. pylori Eradication: 20 mg twice daily for 14 days, in combination with amoxicillin (1000 mg twice daily) and clarithromycin (200-250 mg twice daily) .
\nMissed Dose: If a dose is missed, take it as soon as possible on the same day. Resume the normal schedule the next day. Do not take a double dose .
\n3. Mechanism of Action
\nVonoprazan is a Potassium-Competitive Acid Blocker (P-CAB).
\nUnlike Proton Pump Inhibitors (PPIs) which require activation in acidic environments and form irreversible bonds, Vonoprazan blocks the H+\/K+-ATPase enzyme by competing with potassium ions at the binding site. This allows for rapid, reversible, and strong acid suppression immediately upon administration .
\n4. Safety and Warnings
\nEmbryo-Fetal Toxicity: May cause fetal harm. Use is not recommended during pregnancy or breastfeeding unless the benefit outweighs the risk .
\nHepatotoxicity: Liver function abnormalities have been reported. Monitor liver enzymes periodically .
\nMasking of Gastric Cancer: Treatment may mask symptoms of gastric malignancy. Malignancy should be ruled out before initiating therapy for dyspepsia .
\nRisk of Infections: Increased gastric pH increases susceptibility to infections, including Clostridioides difficile .
\nBone Fracture Risk: Long-term or high-dose use (\u22651 year) has been associated with an increased risk of osteoporosis-related fractures (hip, wrist, spine) .
\n5. Adverse Reactions
\nCommon adverse reactions (incidence \u22651% or frequent in trials) include:
\nGastrointestinal: Diarrhea, Constipation, Nausea, Abdominal distension .
\nHepatic: Elevated liver enzymes (ALT, AST, GGT, ALP) .
\nDermatologic: Rash, Pruritus .
\nNeurologic: Headache .
\n6. Drug Interactions
\nContraindicated: Atazanavir and Rilpivirine (absorption is pH-dependent and significantly reduced) .
\nCYP3A4 Substrates: Vonoprazan is metabolized by CYP3A4. Co-administration with strong inhibitors (e.g., Clarithromycin) increases Vonoprazan exposure .
\npH-Dependent Drugs: May alter absorption of drugs requiring acidic pH (e.g., Itraconazole, Erlotinib, Gefitinib) .
\nDigoxin: Vonoprazan may increase digoxin exposure; monitor levels .
\n7. Pharmaceutical Information
\nChemical Name: 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate .
\nMolecular Formula: C17H16FN3O2S \u00b7 C4H4O4 .
\nStorage: Store at or below 30\u00b0C in a dry place, protected from light .<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u6c83\u514b \u00ae(Vocinti\u00ae)
\nGeneric Name: Vonoprazan Fumarate
\nStrength: 20 mg per tablet
\nManufacturer: Takeda Pharmaceutical Company Limited, Hikari Plant<\/p>\n
Marketing Authorization Holder: Takeda Pharmaceutical Company Limited\uff1b\u5883\u5185\u8d23\u4efb\u4eba\uff1a\u6b66\u7530\uff08\u4e2d\u56fd\uff09\u56fd\u9645\u8d38\u6613\u6709\u9650\u516c\u53f8
\nApproval Date in China: December 18, 2019
\nRegistration Number: \u56fd\u836f\u51c6\u5b57HJ20190065
\nStorage: Seal tightly and store below 30\u2103; keep away from moisture and out of sight and reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Vonoprazan Fumarate\uff08Vocinti\uff09<\/p>\n","protected":false},"featured_media":3041,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[74],"product_cat":[27],"product_tag":[],"class_list":["post-3040","product","type-product","status-publish","has-post-thumbnail","product_brand-takeda","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n